anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: present invention describes method of preparing oral enterosoluble coated drugs. Said drugs comprise compound which is no stable in acid medium. Said drugs are prepared in the form of standard doses which are stable in acid media and obtained by reaction of benzimidazole derivative, which is not stable in acid medium, with cyctodextrin in alkaline solution. EFFECT: more efficient preparation method. 9 cl, 25 tbl
A method of producing a composition for use in the treatment of insulin-dependent diabetes is described. The active ingredient in the composition is a mixture of terpenoids derived from an extract of the tubers of the plant Cyperus rotundus Linn and is administered orally to diabetic patients to provide therapeutic effects such as reducing blood sugar levels. The prepared extract can be in a powder form or in a volatile oil. A comparison of oral administration of equal volumes of the composition and insulin indicates that the composition has about 20% of the effect of insulin, which would be obviated by concentrating the composition. The composition can also be administered parenterally. In clinical trials on humans a flavor enhanced composition derived from an agneous-based paste resulted in significant therapeutic benefit with no side effects. 
     The production of the composition and method of treatment of a diabetic patient is also described.
In this study, it is planned to include about 70 patients each year, assuming two treatments per patient. Due to the post-market nature of the study, this sample size is not based on a formal statistical sample size calculation, but the size is considered appropriate for the study purposes and considering the enrollment rate estimated at the center.
The plant-specific homeodomain-leucine zipper I subfamily is involved in the regulation of various biological processes, particularly growth, development and stress response. In the present study, we characterized four BnaHB6 homologues from Brassica napus. All BnaHB6 proteins have transcriptional activation activity. Structural and functional data indicate the complex role of BnaHB6 genes in regulating biological processes, with some functions conserved and others diverged. Transcriptional analyzes revealed that they are induced in a similar manner in different tissues but show different expression patterns in response to stress and circadian rhythm. Only the BnaA09HB6 and BnaC08HB6 genes are expressed under dehydration and salt stress, and in darkness. The partial transcriptional overlap of BnaHB6s with the evolutionarily related genes BnaHB5 and BnaHB16 was also observed. Transgenic Arabidopsis thaliana plants expressing a single proBnaHB6::GUS partially confirmed the expression results. Bioinformatic analysis allowed the identification of TF-binding sites in the BnaHB6 promoters that may control their expression under stress and circadian rhythm. ChIP-qPCR analysis revealed that BnaA09HB6 and BnaC08HB6 bind directly to the promoters of the target genes BnaABF4 and BnaDREB2A. Comparison of their expression patterns in the WT plants and the bnac08hb6 mutant showed that BnaC08HB6 positively regulates the expression of the BnaABF4 and BnaDREB2A genes under dehydration and salt stress. We conclude that four BnaHB6 homologues have distinct functions in response to stress despite high sequence similarity, possibly indicating different binding preferences with BnaABF4 and BnaDREB2A. We hypothesize that BnaC08HB6 and BnaA09HB6 function in a complex regulatory network under stress.
The novel compound stannous fluorozirconate, SnZrF6, may be prepared by reacting equimolar quantities of SnF2 and ZrF4 in aqueous solution and isolating the product by evaporation.  Alternatively, SnF2 and ZrF4 may be heat-fused.  The white, water-soluble crystals of SnZrF6 may be incorporated in oral compositions since the compound has high anticaries efficacy.ALSO:An oral composition for caries prophylaxis comprises 0.1 to 50% of stannous fluorozirconate, SnZrF6, and an ionically compatible carrier.  Dentifrice compositions, containing say 0.1 to 1% SnZrF6, incorporate abrasives such as particulate condensation products of melamine and urea or formaldehyde, calcium pyrophosphate, calcium, metaphosphate, calcium oxyapatite, b  -and a - tricalcium orthophosphates, insoluble metaphosphates and alumina, together with a foaming agent, binder and flavouring. Colloidal magnesium silicate and a humectant may also be included.  The pH values of the aqueous oral compositions are preferably in the range 4.0 to 5.5.
Automated systems and methods for creating and obtaining devices, including biomedical implants. Systems can have a surgeon's device, an automated platform, and a server. The surgeon's device can send a request for a template of a biomedical implant, and can access tools to edit the template. The automated platform can receive the edited template, and can generate a response. The response can include translating the edited template into a design for a biomedical implant. The response can further include generating a notice if the edited template falls outside of an acceptable range, or if the edited template is similar to the design of a standard biomedical implant. There can also be provided a manufacturing facility that can manufacture the implant and send the implant to the surgeon.
No new adverse reactions to TRUVADA were identified from two randomized placebo-controlled clinical trials (iPrEx, Partners PrEP) in which 2830 HIV-1 uninfected adults received TRUVADA once daily for pre-exposure prophylaxis. Subjects were followed for a median of 71 weeks and 87 weeks, respectively. These trials enrolled HIV-negative individuals ranging in age from 18 to 67 years. The iPrEx trial enrolled only males or transgender females of Hispanic/Latino (72%), White (18%), Black (9%) and Asian (5%) race. The Partners PrEP trial enrolled both males (61–64% across treatment groups) and females in Kenya and Uganda. Table 4 provides a list of all adverse events that occurred ≥2% of subjects in any treatment group in the iPrEx and Partners PrEP trials.

Laboratory Abnormalities: Table 5 provides a list of laboratory abnormalities observed in both trials. Six subjects in the TDF-containing arms of the Partners PrEP trial discontinued participation in the study due to an increase in blood creatinine compared with no discontinuations in the placebo group. One subject in the TRUVADA arm of the iPrEx trial discontinued from the study due to an increase in blood creatinine and another due to low phosphorous.

In addition to the laboratory abnormalities described above, Grade 1 proteinuria (1+) occurred in 6% of subjects receiving TRUVADA in the iPrEx trial. Grades 2–3 proteinuria (2–4+) and glycosuria (3+) occurred in less than 1% of subjects treated with TRUVADA in the iPrEx trial and Partners PrEP trial. 

### 

Changes in Bone Mineral Density:

In clinical trials of HIV-1 uninfected individuals, decreases in BMD were observed. In the iPrEx trial, a substudy of 503 subjects found mean changes from baseline in BMD ranging from -0.4% to -1.0% across total hip, spine, femoral neck, and trochanter in the TRUVADA group compared with the placebo group, which returned toward baseline after discontinuation of treatment. Thirteen percent of subjects receiving TRUVADA vs. 6% of subjects receiving placebo lost at least 5% of BMD at the spine during treatment. Bone fractures were reported in 1.7% of the TRUVADA group compared with 1.4% in the placebo group. No correlation between BMD and fractures was noted [See Clinical Studies (14.2)]. The Partners PrEP trial found similar fracture rates between treatment and placebo groups (0.8% and 0.6%, respectively). No BMD evaluations were conducted during this trial [See Clinical Studies (14.3)].
After the mother is dressed in a clean apron, she will be provided to wash and disinfect her hands and heat her hand temperature with a non-contact fire meter device until the measurement value is 34 ºC.Jul. The mother, who was previously informed about the method, will place the fingertips and palm of one hand above the eyebrow line so that it touches the baby's crown part, while placing the other hand on the lower abdomen surrounding the baby's waist and hips (Figure 1). The GHT application will be started 5 minutes before the blood collection procedure, it will be continued during the blood collection procedure and until 5 minutes after the end of the blood collection procedure.
The novel 7a ,17a -dimethyl-estradiol and the novel 3-methyl ether thereof are prepared by reacting 7a -methyl-estrone or the 3-methyl or -tetrahydropyranyl ether thereof with a methyl metal compound e.g. a Grignard reagent or lithium methyl, and, if necessary, removing the tetrahydropyranyl group.  Examples are given.  7a  - Methyl - estrone tetrahydropyranyl ether is prepred from the free 3-ol and dihydropyran.  The steroids of the invention, which are stated to be highly active estrogens, may be made up into pharmaceutical compositions suitable for enteral or parenteral administration. In addition to carriers they may contain preserving, stabilizing, wetting or emulsifying agents, salts for regulating the osmotic pressure, or buffers.
Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.
PURPOSE: To easily obtain a magnetizable composite microsphere of a hydrophobic crosslinked vinyl arom. polymer suitable for an enzyme carrier or the like by forming a shell of a specified hydrophobic crosslinked copolymer on the outer periphery of a core of a magnetizable fine particle.  
     CONSTITUTION: A magnetizable particle (e.g. magnetite), having a diameter of less than 300×10 -4  μm, coated with a monomolecular layer of a nonaq. dispersant (e.g. oleic acid) is provided. This magnetizable particle is dispersed in a mixture of a hydrophobic vinyl arom. monomer (e.g. styrene) and a polyethylenically unsatd. emulsifiable polymer which is soluble in this monomer and crosslinkable (e.g. a polyester of propylene glycol with maleic anhydride). An organosoluble polymn. primer (e.g. azoisobutyronitrile) is then added to this magnetic fluid, and the mixture is pre-emulsified in water to copolymerize monomers contained in the mixture. The resultant magnetizable microsphere is separated from unmagnetizable microsphere by means of a magnet. Thus, a magnetizable composite microsphere of a hydrophobic crosslinked polymer having a core-shell structure is obtained. 
     COPYRIGHT: (C)1990,JPO
Dosage should be individualized. The initial dose should be low and then increased gradually, especially in patients over 60 years of age. Whether trihexyphenidyl HCl may best be given before or after meals should be determined by the way the patient reacts. Postencephalitic patients, who are usually more prone to excessive salivation, may prefer to take it after meals and may, in addition, require small amounts of atropine which, under such circumstances, is sometimes an effective adjuvant. If trihexyphenidyl HCl tends to dry the mouth excessively, it may be better to take it before meals, unless it causes nausea. If taken after meals, the thirst sometimes induced can be allayed by mint candies, chewing gum or water.
PURPOSE: A composition containing Puerariae Radix extract for enhancing immunity is provided to prevent and suppress immune deficiency and to use a s food, medicinal product, and feed additive. CONSTITUTION: A pharmaceutical composition for enhancing immunity contains 0.1-50 weight% of Puerariae Radix extract as an active ingredient. The extract is isolated using water, low alcohol of 1-4 carbon atoms, or mixture solvent. A health food for enhancing immunity contains Puerariae Radix extract as an active ingredient. The health food is used in the form of powder, granule, tablet, capsule, or beverage. An animal feed additive for enhancing immunity contains the Puerariae Radix extract as an active ingredient.
The present invention provides an improved pediatric formula and methods for providing nutrition to and enhancing tolerance in pediatric patients. The formula may be provided in powder, concentrate or ready-to-feed forms. The pediatric formula comprises, based on a 100 kcal basis, about 8 to about 16 grams carbohydrate (preferably about 9.4 to about 12.3 grams), about 3 to about 6 grams lipid (preferably about 4.7 to about 5.6 grams), about 1.8 to about 3.3 grams protein (preferably about 2.4 to about 3.3 grams), and a tolerance improver comprising a sufficient quantity for xanthum gum to produce a viscosity of no greater than about 200 centipoise at a pH of 4.0, or less. The formula may also be provided in a powder. The formula preferably further comprises vitamins and minerals and may further comprise a stabilizer. The methods comprise administering to a pediatric patient an effective amount of a pediatric formula according to the invention, as described above.
BACKGROUND: This study aimed to assess whether maternal telomere length is a more accurate predictor of trisomy 21 than maternal age while also exploring the factors influencing maternal and fetal telomere length.
METHODS: Forty mothers with fetuses carrying extra maternal copies of chromosome 21 were defined as trisomy 21 cases, and 18 mothers with normal karyotype fetuses were defined as controls. Telomere lengths of maternal blood lymphocytes and amniotic fluid cells were determined using real-time polymerase chain reaction. Fetal and maternal telomere lengths were compared between the two groups. Moreover, we analyzed the factors influencing maternal and fetal telomere length in the trisomy 21 pedigree. A logistic regression model was used to analyze the correlation between maternal telomere length and trisomy 21 risk. In addition, receiver operating characteristic (ROC) curve analysis was used to determine the accuracy of using maternal telomere length as an indicator of trisomy 21 risk.
RESULTS: The study revealed that both maternal and fetal telomere lengths were significantly shorter in trisomy 21 cases than in the controls. In the trisomy 21 group, the maternal age, occupation, and nationality showed no significant correlation with their telomere length; fetal telomere length exhibited a positive correlation with maternal telomere length. Furthermore, maternal telomere length shortening is associated with trisomy 21 (OR = 0.311; 95% CI, 0.109-0.885, P < 0.05). The results of ROC curve analysis indicated that a combined assessment of maternal age and maternal telomere length predicted fetal chromosome trisomy more effectively than a single assessment (area under the curve 0.808, 95% CI, 0.674-0.941, P < 0.001).
CONCLUSION: Maternal age combined with maternal telomere length proved to be a superior predictor of trisomy risk. Additionally, maternal telomere length was found to influence fetal telomere length.
OBJECTIVE: The DSM-5 classification introduced new Feeding and Eating Disorders (FED) diagnostic categories, notably Avoidant and Restrictive Food Intake Disorder (ARFID), which, like other FED, can present psychiatric and gastrointestinal symptoms. However, paediatric clinical research that focuses on children below the age of 12 years remains scarce. The aim of this study was first to investigate the clinical features of FED in a cohort of children, second to compare them according to their recruitment (gastroenterology or psychiatry unit).
METHOD: This non-interventional retrospective cohort study analysed 191 patients in a French paediatric tertiary care centre (gastroenterology n = 100, psychiatry n = 91). The main outcome variables were clinical data (type of FED, BMI, nutritional support, chronic diseases, psychiatric comorbidities, sensory, sleep, language disorders, gastrointestinal complaints, adverse life events, family history). The outcome was defined by a Clinical Global Impression of Change-score.
RESULTS: FED diagnoses were ARFID (n = 100), Unspecified FED (UFED, n = 57), anorexia nervosa (AN, n = 33) and one pica/rumination. Mean follow-up was 3.28 years (SD 1.91). ARFID was associated with selective and sensory disorders (p < 0.001); they had more anxiety disorders than patients with UFED (p < 0.001). Patients with UFED had more chewing difficulties, language disorder (p < 0.001), and more FED related to chronic disease (p < 0.05) than patients with ARFID and AN. Patients with AN were female, underweight, referred exclusively to the psychiatrist, and had more depression than patients with ARFID and UFED (p < 0.001). The gastroenterology cohort included more UFED, while the psychiatry cohort included more psychiatric comorbidities (p < 0.001). A worse clinical outcome was associated with ARFID, a younger age at onset (p < 0.001), selective/sensory disorders and nutritional support (p < 0.05).
CONCLUSION: ARFID and UFED children were diagnosed either by gastroenterologists or psychiatrists. Due to frequently associated somatic and psychiatric comorbidities, children with FED should benefit from a multidisciplinary assessment and care.
Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.
In Germany, one in eight women will develop breast cancer in her lifetime, with a relative 5-year survival rate of 88%. Around 70 % of breast cancer cases are hormone receptor positive. Adjuvant endocrine therapy is recommended to reduce the risk of recurrence.The results of a systematic review show that around 52.4 % to 84.8 % of patients adhere to the treatment. It was also shown that non-adherence to treatment has a negative impact on the risk of breast cancer recurrence and the development of distant metastases, as well as on mortality. Lack of adherence to treatment is related, among other things, to the side effects of endocrine therapy, which significantly reduce quality of life. In particular, musculoskeletal syndrome and sleep disorders lead to discontinuation of endocrine treatment with an aromatase inhibitor. Many patients also suffer from hot flashes, sexual dysfunction, weight gain, bone density loss, depression, cognitive dysfunction and fatigue.

The study focuses on hot flashes, which have a negative impact on sleep and promote symptoms of fatigue. Due to the endocrine therapy, the symptoms are usually more pronounced than the menopause-related symptoms. However, oestrogen-based hormone replacement therapy is contraindicated, while non-hormonal medication such as venlafaxine or gabapentin often have serious side effects. An alternative is body acupuncture, which can decrease hot flashes in women with breast cancer. One of the advantages of acupuncture compared to drug treatments is that it is considered having very few side effects.

With the help of a three-armed randomized controlled research design, this study aims to investigate the efficacy and effectiveness of balanced ear acupuncture compared to NADA ear acupuncture in the treatment of hot flashes caused by endocrine therapy. In addition, the effects of the two forms of therapy on the individual quality of life, fatigue, stress perception and sleep quality of the patients will be analyzed.The respective results will be compared with those of a control group that did not receive acupuncture during the observation period.
Dry eye disease is prevalent among patients presenting with ocular surface diseases, with rates ranging from 5-50% in recent years. In the United States, approximately sixteen million people are affected by this condition. Dry eye patients often experience ocular surface damage, such as punctate epithelial keratitis, superior limbic keratoconjunctivitis, and filamentary keratitis, due to impaired tear lubrication of the cornea. The etiology of dry eye disease is multifactorial, making diagnosis challenging and requiring comprehensive medical history inquiry and various ocular surface staining techniques. In Taiwan, fluorescein strips are commonly used to assess corneal damage severity and tear break-up time to evaluate tear film abnormalities. Recent research utilizing in vivo confocal microscopy has revealed lower sub-basal nerve fiber numbers and higher dendritic cell densities in the cornea of dry eye patients with immune causes.

Dry eye disease was redefined as a multifactorial condition at the International Dry Eye Workshop II (DEWS II) in 2017, categorized into aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE). In Taiwan, Sjögren's Syndrome (SS) is a primary cause of aqueous deficient dry eye, occurring in approximately 4.8% of dry eye disease patients. SS is a chronic autoimmune disease characterized by lymphocyte infiltration of exocrine glands like the salivary and lacrimal glands. If SS occurs without other autoimmune diseases, it is referred to as primary Sjögren's Syndrome (pSS). Globally, the prevalence of pSS is approximately 60.82 per 100,000 people, with an incidence rate of 6.92 per 100,000 people. Conventional diagnostic methods for salivary dysfunction, such as salivary scintigraphy and parotid sialography, are costly and time-consuming. Following SS diagnosis, comprehensive blood tests, including CBC, DC, ESR, CRP, BUN, Cre, Na, K, HCO3, and serum immunomarkers (ANA, anti-SSA/Ro, anti-SSB/La, RF), are typically advised. The study aims to investigate saliva conductivity as a diagnostic and disease activity monitoring tool for primary Sjögren's syndrome in dry eye syndrome patients and its association with ocular surface damage and tear secretion volume.